ADVA
20.5.2020 09:02:09 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that it has upgraded its complete portfolio of Oscilloquartz PTP grandmaster clocks, enabling power utilities to smoothly transition to packet network synchronization. The enhanced technology will empower electricity providers to evolve their infrastructure into smart grids based on Precision Time Protocol (PTP) power profiles, while at the same time supporting all legacy timing signals. Updates to ADVA’s Oscilloquartz pluggable solution, its compact small cell device, its mid-size PTP grandmasters and its fully redundant core timing technology ensure ultra-precise timing throughout the utility network. What’s more, the technology removes the risk of relying purely on satellite-based time sources through continuous monitoring, jamming and spoofing detection and AI-assisted analytics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200520005048/en/
“Our upgraded technology makes it simple to modernize utility infrastructure. Now, power network operators can achieve the accurate and stable synchronization needed to develop smart grid power networks built on packet-based solutions, while also maintaining legacy timing,” said Gil Biran, general manager, Oscilloquartz, ADVA. “Our technology provides a clear and cost-efficient path to robust and future-proof utility network synchronization. Its PTP timing delivery complements and replaces legacy protocols, enabling the accurate and resilient timing needed for emerging intelligent applications. Along with our multi-constellation GNSS receivers, PTP backup is also essential for protecting critical power networks. This ensures efficient operations and the best protection from malicious attacks.”
ADVA’s entire range of Oscilloquartz grandmaster clocks has been upgraded to meet the latest PTP profiles for time, frequency and phase synchronization in power utility networks. This includes the OSA 5401 small form-factor pluggable, the OSA 5405 for indoor and outdoor substation deployments, the OSA 5420 Series, and the highly scalable OSA 5430 and 5440 with 10Gbit/s interfaces and fully redundant hardware. The technologies enable an easy migration to an Ethernet-based timing network with support for PTP, Network Time Protocol (NTP) and SyncE, as well as IRIG-B, PPS and BITS legacy interfaces. PTP-based backup combined with multi-band GNSS receivers and advanced monitoring capabilities ensure that the upgraded solutions provide highly reliable delivery of precise timing information even during long GNSS outages. And, to create an ePRTC solution, ADVA’s Oscilloquartz cesium clocks can also be combined with the OSA 5420, 5430 or 5440. This delivers extended holdover of up to 70 nanoseconds for 14 days, even when GNSS signals are unavailable.
”By optimizing our synchronization technology, we’re enabling power utilities to achieve the stringent levels of precision necessary for synchronization from the substation to the core of the smart grid network. Our comprehensive portfolio empowers utilities to complement and then replace their legacy timing protocols with PTP. What’s more, our continually evolving software supports the broadest range of interfaces and profiles, ensuring a solution ready to grow with future needs,” commented Nir Laufer, senior director, product line management, Oscilloquartz, ADVA. ”IRIG-B and NTP have served the utility industry well. But the future is all about PTP power profiles delivering new levels of precision and reliability to substations with or without GNSS. This upgrade ensures operators can rely on extremely accurate frequency, phase and time services without the threat of outages caused by jamming and spoofing.”
Watch this video for more information: https://youtu.be/iHA_TI32T6A .
Further details are also provided in these slides: https://adva.li/power-utilities-slides .
A supporting solution sheet is available here: https://adva.li/smart-grids-solution-sheet .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at www.oscilloquartz.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200520005048/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom